Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Spinraza
Pharma
Biogen reports promising results for higher dose of Spinraza
A trial of Biogen’s spinal muscular atrophy therapy Spinraza suggests that a higher dose provides benefits to a broad range of patients.
Kevin Dunleavy
Oct 9, 2024 7:30am
Biogen to seek approval for high-dose version of Spinraza
Sep 4, 2024 11:45am
Biogen CEO plots turnaround after 'weak' 2023 performance
Feb 13, 2024 11:28am
Biogen pays $7.3B to acquire Reata and newly approved Skyclarys
Jul 28, 2023 11:17am
Reduction of 1,000 jobs will cut Biogen's workforce by 11.5%
Jul 25, 2023 11:05am
Biogen's new CEO looks to ads to boost new drugs
Feb 16, 2023 9:10am
